The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial

Basit Öğe Kaydı
dc.WoS.categoriesOncologyen_US
dc.authorid0000-0003-0917-2098en_US
dc.contributor.authorDuymaz, Tomris
dc.date.accessioned2020-11-11T08:47:08Z
dc.date.available2020-11-11T08:47:08Z
dc.date.issued2020-07
dc.description8 pagesen_US
dc.description.abstractObjective: Premenopausal women with breast cancer arc at risk of developing ovarian failure after chemotherapy. The aim of this study was to investigate the negative effects of systemic chemotherapy on ovarian function in premenoupausal women with breast cancer. Materials and Methods: Thirty-one premenopausal women with operable breast cancer aged between 26-48 years were enrolled in this prospective cohort study CO investigate preliminary results. Additional 69 patients data will be included after the completion of all five measurements. The change in serum Antimullerian Hormone (AMH) levels, mean ovarian volumes (MOV) and antral follicle counts (AFCs) at 3-month intervals were recorded to evaluate ovarian function. Women who had at least one pretreatment and four post-treatment measurements in one year follow-up period were included in the study. Decision of chemotherapy regimen was taken by the Tumor Board. Results: Thirty-one patients had all five AMH, MOV and AFCs results. There was a statistically significant negative correlation between 1st - 5th AMH levels (p=0.006) and 1st - 5th AFCs during the follow-up period (p<0.0001). However pie- and post-chemotherapy measurements of MOVs did not demonstrate any significant correlation (p=0.799). BMI, parity, lactation, him pathology and molecular subtypes of breast cancer, alcohol intake, smoking and type of chemotherapy regimen were not significantly correlated with AMH, AFC and MOV. Conclusion: Pretreatment AMH levels and AFC were shown to have a significant role in early prediction of ovarian-reserve after chemotherapy.en_US
dc.fullTextLevelFull Texten_US
dc.identifier.doi10.5152/ejbh.2020.5114en_US
dc.identifier.issn2587-0831
dc.identifier.pmid32656517en_US
dc.identifier.scopus2-s2.0-85130462901en_US
dc.identifier.trdizinid380768en_US
dc.identifier.urihttps://hdl.handle.net/11411/2593
dc.identifier.urihttps://doi.org/10.5152/ejbh.2020.5114
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/380768en_US
dc.identifier.wosWOS:000547335300006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.issue3en_US
dc.language.isoenen_US
dc.nationalInternationalen_US
dc.numberofauthors11en_US
dc.pages177-182en_US
dc.publisherAvesen_US
dc.relation.ispartofEuropean Journal Of Breast Healthen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChemotherapyen_US
dc.subjectBreast canceren_US
dc.subjectAMHen_US
dc.subjectOvarian reserveen_US
dc.titleThe Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trialen_US
dc.typeArticleen_US
dc.volume16en_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
2020WoSDuymaz.pdf
Boyut:
1023.96 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Faculty of Health Sciences
PubMed Indexed Publications
Scopus Indexed Publications
TR Dizin Indexed Publications
Web of Science Indexed Publications